Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).

(2017) M. R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

(2012) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

(2012) Monika E. Hegi et al.   ACTA NEUROPATHOLOGICA

1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth

(2012) Catherine Gozé et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

IDH1mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival

(2011) Niklas Thon et al.   CANCER

Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

(2011) C. Hartmann et al.   CLINICAL CANCER RESEARCH

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

(2011) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size

(2011) David Capper et al.   INTERNATIONAL JOURNAL OF CANCER

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial

(2011) Jaime Gállego Pérez-Larraya et al.   JOURNAL OF CLINICAL ONCOLOGY

Should All Women With Breast Cancer Be Tested forBRCAMutations at the Time of Diagnosis?

(2011) Steven A. Narod   JOURNAL OF CLINICAL ONCOLOGY

Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

(2011) Stephen Yip et al.   JOURNAL OF PATHOLOGY

Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas

(2011) M. Kunz et al.   NEURO-ONCOLOGY

Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma

(2011) C. Bettegowda et al.   SCIENCE

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

(2010) Martin J. van den Bent   ACTA NEUROPATHOLOGICA

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

(2009) H. J. Dubbink et al.   NEUROLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE